Latest Europe News

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.

Stakk Ltd aims to nearly double its annual recurring revenue to $15 million by mid-2026, driven by a strong enterprise pipeline and a flagship deployment of its new Mobile IQ SDK with Robinhood. This move underscores Stakk’s growing footprint in embedded finance security.

SRJ Technologies has completed the first phase of its growth strategy and is now advancing into market penetration with a significant $23.8 million joint venture in the Middle East and a key board appointment.

Spacetalk Ltd has completed a major pivot from hardware to a scalable software-as-a-service model, driving a 26% increase in active mobile subscribers and a 9% rise in annual recurring revenue to $12 million.

BrainChip Holdings has bolstered its financial position with a A$35 million capital raise and commenced volume production of its AKD1500 neuromorphic AI chip, while deepening its strategic partnership with Parsons’ defence arm.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.

Arafura Rare Earths has raised A$481 million in equity funding and secured key government backing, advancing its Nolans Project towards a final investment decision in 2026.